Successful Treatment of Systemic Lupus Erythematosus with Subcutaneous Immunoglobulin

Detalhes bibliográficos
Autor(a) principal: Brasileiro, A
Data de Publicação: 2016
Outros Autores: Fonseca Oliveira, J, Pinheiro, S, Paiva-Lopes, MJ
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/2847
Resumo: The therapeutic efficacy of high-dose intravenous immunoglobulin in systemic lupus erythematosus (SLE) patients is well established. However, side effects might limit its use and lead to the consideration of therapeutic alternatives, such as the subcutaneous formulation of immunoglobulin, which has been used in some patients with other autoimmune diseases. We report a case of SLE refractory to classical therapies. High-dose intravenous immunoglobulin was effective, but gave rise to significant side effects. The patient was successfully treated with subcutaneous human immunoglobulin, achieving and maintaining clinical and laboratory remission. A lower immunoglobulin dose was needed and no side effects were observed, compared to the intravenous administration. Subcutaneous immunoglobulin could be a better-tolerated and cost-saving therapeutic option for select SLE patients.
id RCAP_019c69440f4d22961b6b7b207fbceddb
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/2847
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Successful Treatment of Systemic Lupus Erythematosus with Subcutaneous ImmunoglobulinDose-Response Relationship, DrugFemaleHumansImmunoglobulinsImmunoglobulins, IntravenousImmunologic FactorsInjections, SubcutaneousLupus Erythematosus, SystemicMiddle AgedTreatment OutcomeHSAC DERHSAC MEDThe therapeutic efficacy of high-dose intravenous immunoglobulin in systemic lupus erythematosus (SLE) patients is well established. However, side effects might limit its use and lead to the consideration of therapeutic alternatives, such as the subcutaneous formulation of immunoglobulin, which has been used in some patients with other autoimmune diseases. We report a case of SLE refractory to classical therapies. High-dose intravenous immunoglobulin was effective, but gave rise to significant side effects. The patient was successfully treated with subcutaneous human immunoglobulin, achieving and maintaining clinical and laboratory remission. A lower immunoglobulin dose was needed and no side effects were observed, compared to the intravenous administration. Subcutaneous immunoglobulin could be a better-tolerated and cost-saving therapeutic option for select SLE patients.SAGE PublicationsRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEBrasileiro, AFonseca Oliveira, JPinheiro, SPaiva-Lopes, MJ2018-01-15T16:28:21Z2016-052016-05-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/2847engLupus. 2016 May;25(6):663-5.10.1177/0961203316630116info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:39:56Zoai:repositorio.chlc.min-saude.pt:10400.17/2847Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:20:10.860956Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Successful Treatment of Systemic Lupus Erythematosus with Subcutaneous Immunoglobulin
title Successful Treatment of Systemic Lupus Erythematosus with Subcutaneous Immunoglobulin
spellingShingle Successful Treatment of Systemic Lupus Erythematosus with Subcutaneous Immunoglobulin
Brasileiro, A
Dose-Response Relationship, Drug
Female
Humans
Immunoglobulins
Immunoglobulins, Intravenous
Immunologic Factors
Injections, Subcutaneous
Lupus Erythematosus, Systemic
Middle Aged
Treatment Outcome
HSAC DER
HSAC MED
title_short Successful Treatment of Systemic Lupus Erythematosus with Subcutaneous Immunoglobulin
title_full Successful Treatment of Systemic Lupus Erythematosus with Subcutaneous Immunoglobulin
title_fullStr Successful Treatment of Systemic Lupus Erythematosus with Subcutaneous Immunoglobulin
title_full_unstemmed Successful Treatment of Systemic Lupus Erythematosus with Subcutaneous Immunoglobulin
title_sort Successful Treatment of Systemic Lupus Erythematosus with Subcutaneous Immunoglobulin
author Brasileiro, A
author_facet Brasileiro, A
Fonseca Oliveira, J
Pinheiro, S
Paiva-Lopes, MJ
author_role author
author2 Fonseca Oliveira, J
Pinheiro, S
Paiva-Lopes, MJ
author2_role author
author
author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Brasileiro, A
Fonseca Oliveira, J
Pinheiro, S
Paiva-Lopes, MJ
dc.subject.por.fl_str_mv Dose-Response Relationship, Drug
Female
Humans
Immunoglobulins
Immunoglobulins, Intravenous
Immunologic Factors
Injections, Subcutaneous
Lupus Erythematosus, Systemic
Middle Aged
Treatment Outcome
HSAC DER
HSAC MED
topic Dose-Response Relationship, Drug
Female
Humans
Immunoglobulins
Immunoglobulins, Intravenous
Immunologic Factors
Injections, Subcutaneous
Lupus Erythematosus, Systemic
Middle Aged
Treatment Outcome
HSAC DER
HSAC MED
description The therapeutic efficacy of high-dose intravenous immunoglobulin in systemic lupus erythematosus (SLE) patients is well established. However, side effects might limit its use and lead to the consideration of therapeutic alternatives, such as the subcutaneous formulation of immunoglobulin, which has been used in some patients with other autoimmune diseases. We report a case of SLE refractory to classical therapies. High-dose intravenous immunoglobulin was effective, but gave rise to significant side effects. The patient was successfully treated with subcutaneous human immunoglobulin, achieving and maintaining clinical and laboratory remission. A lower immunoglobulin dose was needed and no side effects were observed, compared to the intravenous administration. Subcutaneous immunoglobulin could be a better-tolerated and cost-saving therapeutic option for select SLE patients.
publishDate 2016
dc.date.none.fl_str_mv 2016-05
2016-05-01T00:00:00Z
2018-01-15T16:28:21Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/2847
url http://hdl.handle.net/10400.17/2847
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Lupus. 2016 May;25(6):663-5.
10.1177/0961203316630116
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv SAGE Publications
publisher.none.fl_str_mv SAGE Publications
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131297911668736

Registros relacionados